All In Biotech

Drug Trial Radar · NCT00233402

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer

Last checked: Nov 20, 2026Latest source record: Oct 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 789 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

789

Actual

Start

Jan 2005

Primary completion

Jul 2008

Study completion Aug 2008

Sponsor

Lead sponsor
PhotocureIndustry
Sponsor type
Industry
First posted
Oct 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.

Conditions

  • Bladder Cancer

Interventions

  • HexvixDrug

    Single Instillation, Transurethral Resection of the Bladder

  • Standard white light cystoscopyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White LightTime frame: Day 0
  2. Comparison of the Proportions of Patients in the White Light Cystoscopy and Hexvix Groups Who Underwent TURB for a Histologically-confirmed Ta or T1 Tumor Who Had a Recurrence ( CIS, Ta, T1 or T2-T4 Tumor) Within 9 Months.Time frame: 9 months

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center, Department of Urology

    Stanford, California

  • V.A. Medical Center

    Gainesville, Florida

  • University of Miami School of Medicine

    Miami, Florida

  • South Florida Clinical Research Center, Inc.

    Pembroke Pines, Florida

  • The Emory Clinic, Dept of Urology

    Atlanta, Georgia

  • Boston University School of Medicine

    Boston, Massachusetts

  • St. Joseph Mercy Hospital- Ann Arbor

    Ann Arbor, Michigan

  • Urologic Clinical Research Unit, Gonda 7102, Mayo Clinic Rochester

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai Medical Center, Department of Urology

    New York, New York

  • URMC

    Rochester, New York

  • Urological Institute at Beachwood Cleveland Clinic

    Beachwood, Ohio

  • Thomas Jefferson Medical College, Department of Neurology

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center, Department of Urologic Surgery

    Nashville, Tennessee

  • Baylor College of Medicine, Scott Department of Urology

    Houston, Texas

  • AKH, Klinik für Urologie der Universität Wien

    Vienna, Austria

  • CHUQ Hotel-Dieu de Quebec

    Québec, Canada

  • Kingston General Hospital

    Kingston, Ontario, Canada

  • University Clinic of Giessen, Department of Urology

    Giessen, Germany

  • Klinikum der Universität München-Großhardern, Urologische Klinik und Poliklinik

    München, Germany

  • Urologische Klinik München-Planegg

    Planegg, Germany

  • Akadem. Lehrkrankenhaus der Uni Regensburg, Klinik für Urologie

    Regensburg, Germany

  • Universitätsklinik Tuebingen, Universitätsklinik für Urologie

    Tübingen, Germany

  • Department of Urology, Academic Medical Center, University of Amsterdam

    Amsterdam, Netherlands

  • Department of Urology, UMC St. Radboud

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.